Dexcom announced the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes will ...
Dexcom’s “Smart Basal” has received FDA clearance for people with type 2 diabetes using long-acting insulin. The feature will ...
Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next ...
Zacks Investment Research on MSN
DXCM Stock Falls Despite FDA Clearance for Dexcom Smart Basal
DexCom DXCM recently announced that it has received FDA clearance for its CGM-integrated basal insulin dosing optimizer, ...
Dexcom Inc. received U.S. FDA clearance for its Smart Basal CGM-integrated basal insulin dosing optimizer. Designed for adults with type 2 diabetes using glargine U-100 long-acting insulin therapy, ...
Abstract: This paper delves into the output feedback sliding mode control (SMC) problems in a class of Interval Type-2 (IT2) fuzzy systems affected by sensor faults. Firstly, a Markovian chain is ...
Fintel reports that on October 31, 2025, Canaccord Genuity maintained coverage of DexCom (NasdaqGS:DXCM) with a Buy recommendation. Analyst Price Forecast Suggests 75.44% Upside As of October 30, 2025 ...
Abstract: Autonomous vehicles increasingly rely on camera-based computer vision systems to perceive environments and make critical driving decisions. To improve image quality, image stabilizers with ...
SAN DIEGO (AP) — SAN DIEGO (AP) — DexCom Inc. (DXCM) on Thursday reported third-quarter net income of $283.8 million. The San Diego-based company said it had net income of 70 cents per share. Earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback